B7H3/CD28 targeted BsAb (Wuxi Biologics)

B7H3/CD28双抗 (无锡药明生物)

Report date: 2026/05/18 20:02:07

Base Information

Drug NameB7H3/CD28 targeted BsAb (Wuxi Biologics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-CD28Anti-CD276
TargetsT-cell-specific surface glycoprotein CD28CD276 antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuxi Biologics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuxi Biologics Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A